Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels for gastric cancer-risk screening
Description: Helicobacter pylori infection and the degree of chronic atrophic gastritis are significant predictors for the development of gastric cancer, especially in the Japanese population. A combination of assays for serum anti-Helicobacter pylori immunoglobulin G antibody (HPA) and serum pepsinogen (PG) levels can be used to identify gastric cancer risk. In Japan, this ABC method may be an effective approach for identifying high-risk individuals who should undergo gastric cancer screening. The present study’s purpose was to estimate the long-term cost-effectiveness of the ABC method for assessing the gastric cancer risk in a Japanese population. We constructed a Markov cohort model to estimate the cost-effectiveness of ABC method. We suggested that a combination of HPA and serum PG assays plus scheduling endoscopy accordingly is a cost-effective strategy of screening for gastric cancer risk in Japan.
Amount: ¥4,680,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (C)
Start date: 2016-04-01
End date: 2019-03-31
Investigator: Shota Saito
Institution: Niigata University of Health and Welfare
Funded outputs count: 2
Funder award ID: 16K08889
OpenAlex ID: G4557602013